<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Scopolamine (hyoscine): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Scopolamine (hyoscine): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Scopolamine (hyoscine): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12304" href="/d/html/12304.html" rel="external">see "Scopolamine (hyoscine): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16045" href="/d/html/16045.html" rel="external">see "Scopolamine (hyoscine): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9522574"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Transderm Scop (1.5 MG) [DSC];</li>
<li>Transderm-Scop</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52870234"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACCEL-Hyoscine;</li>
<li>Buscopan</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9523602"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticholinergic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F9522653"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Each transdermal patch delivers ~1 mg scopolamine base over 3 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> In Canada, additional formulations include parenteral and oral scopolamine <i>butylbromide</i> (also known as hyoscine butylbromide) as well as parenteral scopolamine <i>hydrobromide </i>(also known as hyoscine hydrobromide). Scopolamine <i>butylbromide</i> and scopolamine <i>hydrobromide</i> formulations are not equivalent and are <b>not </b>interchangeable on a milligram-to-milligram basis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations: </b>Parenteral scopolamine <i>hydrobromide</i> is approved in Canada for preoperative reduction of oropharyngeal secretions and as an adjunct to anesthesia for sedation and amnesia; however, these uses may no longer represent current clinical practice (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Galvagno.1','lexi-content-ref-Grant.1','lexi-content-ref-ICSI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Galvagno.1','lexi-content-ref-Grant.1','lexi-content-ref-ICSI.1'])">Ref</a></span>); refer to manufacturer's labeling for additional information. Scopolamine <i>butylbromide</i> salt is a quaternary derivative with fewer CNS effects compared with scopolamine <i>hydrobromide</i> and base (patch) formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12380654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12380654'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="469b56a2-0c1b-41d6-bb77-c6b03344ce45">Gastrointestinal/genitourinary spasm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal/genitourinary spasm: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> American College of Gastroenterology guidelines recommend against use of antispasmodics such as scopolamine for treatment of <b>global symptoms</b> of irritable bowel syndrome (IBS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33315591']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33315591'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Scopolamine (hyoscine) <b>butylbromide</b> [Canadian product]:</i>
<b>Oral:</b> 10 to 20 mg 3 to 5 times/day as needed; maximum: 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19337628','lexi-content-ref-23865591','lexi-content-ref-16817918','lexi-content-ref-17547475','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19337628','lexi-content-ref-23865591','lexi-content-ref-16817918','lexi-content-ref-17547475','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> When used for chronic symptom control, 10 mg 3 to 5 times/day as needed is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i></i>
<i>Scopolamine (hyoscine) <b>butylbromide</b> [Canadian product]:</i>
<b>IM/IV/SUBQ:</b> 10 to 20 mg once; if needed, may repeat at intervals of ≥30 minutes; maximum: 100 mg/day. <b>Note:</b> To avoid a potentially severe infusion reaction (ie, hypotension), a maximum rate of 20 mg/minute is preferred.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f9713d91-1d0c-468e-8da9-5311ed886b2f">Malignant bowel obstruction, inoperable</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant bowel obstruction, inoperable</b>
<b>(off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Decreases gastric secretions, nausea, and vomiting; often given as part of a combination regimen (eg, with analgesic, antiemetic, or corticosteroid) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17280927','lexi-content-ref-Wilcock.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17280927','lexi-content-ref-Wilcock.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Scopolamine (hyoscine) <b>butylbromide</b> [Canadian product]:</i>
<b>SUBQ</b>
<b>:</b> Initial: 20 mg once followed by 60 mg over 24 hours as a continuous SUBQ infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10789958','lexi-content-ref-25889313','lexi-content-ref-Wilcock.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10789958','lexi-content-ref-25889313','lexi-content-ref-Wilcock.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="38c7211a-1d16-4e35-9ec1-48325e301558">Motion sickness, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Motion sickness, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Scopolamine base</i>: <b>Transdermal:</b> Apply 1 patch (1 mg/3 days) behind ear at least 4 hours prior to required antiemetic effect for use up to 72 hours; if needed for &gt;72 hours, remove old patch and place new one behind other ear. If symptoms are not adequately controlled with use of 1 patch, may consider using 2 patches (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19698013','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19698013','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="511c4354-e6fc-437d-a529-64fee63ac1be">Postoperative nausea and/or vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and/or vomiting, prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Scopolamine base</i>: <b>Transdermal:</b> Apply 1 patch (1 mg/3 days) behind ear at least 1 to 2 hours prior to anesthesia or night before, and remove 24 hours after procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21118734','lexi-content-ref-32467512','lexi-content-ref-7639364','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21118734','lexi-content-ref-32467512','lexi-content-ref-7639364','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d4c15035-f4ec-4814-9029-cd0375c0f277">Sialorrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sialorrhea (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Note:</b> May be used to control excessive salivation associated with neuromuscular disorders (eg, cerebral palsy, amyotrophic lateral sclerosis [ALS]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20565460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20565460'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Scopolamine base</i>: <b>Transdermal:</b> Apply 1 patch (1 mg/3 days) behind ear; after 3 days, remove old patch and place new one behind other ear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3047394','lexi-content-ref-20565460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3047394','lexi-content-ref-20565460'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="265069ca-50ac-4be8-8c60-2478dc1ae8d4">Terminal airway secretions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Terminal airway secretions (death rattle) (off-label use) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Does not dry secretions already present and typically ineffective for lower respiratory tract secretions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10858832','lexi-content-ref-34609452']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10858832','lexi-content-ref-34609452'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Scopolamine base</i>: <b>Transdermal:</b> Apply 1 patch (1 mg/3 days) behind ear for up to 72 hours; if needed for &gt;72 hours, remove old patch and place new one behind other ear (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Harman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Harman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Scopolamine (hyoscine) <b>butylbromide</b> [Canadian product]</i>: Various regimens described; refer to local protocols. Example regimens include: <b>SUBQ:</b> 20 mg every 4 to 6 hours as needed. Alternatively, administer 20 mg once followed by a continuous SUBQ infusion of 20 to 60 mg over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Harman.1','lexi-content-ref-10858832','lexi-content-ref-34609452','lexi-content-ref-19361952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Harman.1','lexi-content-ref-10858832','lexi-content-ref-34609452','lexi-content-ref-19361952'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991284"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Scopolamine (hyoscine) <i>butylbromide </i>
<i>[Canadian product]</i>: No dosage adjustment likely to be necessary due to limited systemic absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17547475','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17547475','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Parenteral: </b>Scopolamine (hyoscine) <i>butylbromide </i>
<i>[Canadian product]</i>: There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied). Use with caution (~42% to 61% of a total dose is excreted in the urine) with frequent monitoring for adverse effects. If using for &gt;48 hours in patients with eGFR &lt;50 mL/minute/1.73 m<sup>2</sup>, consider reducing the dose or prolonging the dosing interval to prevent accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal: </b>Scopolamine base: No dosage adjustment likely to be necessary (&lt;10% of a total dose is excreted in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use with caution and frequent monitoring in patients with severe kidney disease due to possible increased risk of CNS adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Dialyzability unknown:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Scopolamine (hyoscine) <i>butylbromide</i>
<i>[Canadian product]</i>
<b>:</b> No dosage adjustment likely to be necessary due to limited systemic absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17547475','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17547475','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Parenteral:</b> Scopolamine (hyoscine) <i>butylbromide </i>
<i>[Canadian product]</i>
<i>:</i> There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution (~42% to 61% of a total dose is excreted in the urine) with frequent monitoring for adverse effects. If using for &gt;48 hours, consider reducing the dose or prolonging the dosing interval to prevent accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal:</b> Scopolamine base: No dosage adjustment likely to be necessary (&lt;10% of a total dose is excreted in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use with caution with frequent monitoring for adverse effects due to possible increased risk of CNS adverse effects (manufacturer's labeling); a case of ventricular tachycardia has also been reported in a patient with end-stage kidney disease (ESKD) and concomitant hepatic dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25882751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25882751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>Dialyzability unknown:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Scopolamine (hyoscine) <i>butylbromide</i>
<i>[Canadian product]</i>
<b>:</b> No dosage adjustment likely to be necessary due to limited systemic absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Parenteral:</b> Scopolamine (hyoscine) <i>butylbromide </i>
<i>[Canadian product]</i>
<i>:</i> There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution (~42% to 61% of a total dose is excreted in the urine) with frequent monitoring for adverse effects. If using for &gt;48 hours, consider reducing the dose or prolonging the dosing interval to prevent accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal:</b> Scopolamine base: No dosage adjustment likely to be necessary (&lt;10% of a total dose is excreted in the urine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use with caution with frequent monitoring for adverse effects due to possible increased risk of CNS adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); a case of ventricular tachycardia has also been reported in a patient with ESKD and concomitant hepatic dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25882751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25882751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Scopolamine (hyoscine) <i>butylbromide</i>
<i>[Canadian product]</i>
<b>:</b> No dosage adjustment likely to be necessary due to limited systemic absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Parenteral:</b> Scopolamine (hyoscine) <i>butylbromide </i>
<i>[Canadian product]</i>
<i>:</i> There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution with frequent monitoring for adverse effects. If using for &gt;48 hours, consider reducing the dose or prolonging the dosing interval to prevent accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal:</b> Scopolamine base: No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Scopolamine (hyoscine) <i>butylbromide</i>
<i>[Canadian product]</i>
<b>:</b> No dosage adjustment likely to be necessary due to limited systemic absorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Parenteral:</b> Scopolamine (hyoscine) <i>butylbromide </i>
<i>[Canadian product]</i>
<i>:</i> There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution with frequent monitoring for adverse effects. If using for &gt;48 hours, consider reducing the dose or prolonging the dosing interval to prevent accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Transdermal:</b> Scopolamine base: No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988598"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, caution is recommended due to increased risks of adverse effects.</p></div>
<div class="block doe drugH1Div" id="F9522654"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F9522652"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16045" href="/d/html/16045.html" rel="external">see "Scopolamine (hyoscine): Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosing presented is for scopolamine (hyoscine) hydrobromide; it should not be interchanged with scopolamine butylbromide formulations. Transdermal patch is designed to deliver 1 mg over 3 days. Do not cut patch to obtain smaller increments; remove only portions of the backing required for the dose (eg, if <sup>1</sup>/<sub>2</sub> patch is needed, remove only <sup>1</sup>/<sub>2</sub> of the backing prior to application), cover with occlusive dressing to keep in place (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32943036','lexi-content-ref-29192000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32943036','lexi-content-ref-29192000'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d66ab3f-5bae-4acc-9e7b-434c45ace118">Chronic drooling</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic drooling:</b> Limited data available: Children ≥3 years and Adolescents: Transdermal: Initial: Apply <sup>1</sup>/<sub>4</sub> patch every 3 days for 1 week; may titrate to effect (control of secretions) by increasing by <sup>1</sup>/<sub>4</sub> patch every 7 days as tolerated. Maximum dose: 1 patch applied every 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32943036','lexi-content-ref-7516297','lexi-content-ref-20565460','lexi-content-ref-29192000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32943036','lexi-content-ref-7516297','lexi-content-ref-20565460','lexi-content-ref-29192000'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on retrospective and prospective studies. In one study, patients weighing ≥10 kg with neurodisabilities and chronic drooling (n=85, median age: 4.9 years, range: 3 to 14.5 years) were randomized to receive glycopyrrolate or scopolamine patches. Medications were titrated to effect at weekly intervals. While both glycopyrrolate and scopolamine controlled secretions, scopolamine was associated with more adverse reactions such as skin reactions, gait disturbances, and hyperactivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29192000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29192000'])">Ref</a></span>). In another study, children with developmental delay and chronic drooling (n=10, ages: 5 to 18 years) received scopolamine patches or placebo for 2 weeks, followed by a 1 week washout and then scopolamine patches or placebo for 2 weeks. Doses were initiated at a full patch. Scopolamine showed a significant reduction in drooling. Adverse effects reported were pupil dilation, skin reactions, and increased oral mouthing behaviors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7516297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7516297'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae1bcfa5-9563-4c6b-a1af-01aa4e2e9d9d">Postoperative nausea and vomiting, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and vomiting, prevention:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;2 years: Transdermal: Apply <sup>1</sup>/<sub>4</sub> patch the evening before surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2065410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2065410'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 to 6 years: Transdermal: Apply <sup>1</sup>/<sub>2</sub> patch the evening before surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2065410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2065410'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 to 12 years: Transdermal: Apply <sup>1</sup>/<sub>2</sub> to 1 patch the evening before surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8110556','lexi-content-ref-2065410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8110556','lexi-content-ref-2065410'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Transdermal: Apply 1 patch the evening before surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8110556','lexi-content-ref-21773046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8110556','lexi-content-ref-21773046'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dosing based on 2 small, placebo-controlled studies. In the first study, patients undergoing strabismus surgery received scopolamine (n=25, age: 5.7 ± 2.9 years) or placebo (n=25, age: 5.3 ± 2.7 years) the evening prior to surgery. Children &lt;2 years of age received <sup>1</sup>/<sub>4</sub> patch and children 2 to 11 years of age received <sup>1</sup>/<sub>2</sub> patch. Patients receiving scopolamine experienced less vomiting (16% compared to 48%) and only experienced 1 episode of vomiting, compared to the placebo group which experienced 1 to 7 episodes of vomiting. No side effects were observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2065410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2065410'])">Ref</a></span>). In another study, patients undergoing abdominal surgery received scopolamine (n=20, ages: 6.3 to 14.1 years) or placebo (n=20, ages: 7.2 to 14.3 years) at the start of surgery. Scopolamine was associated with a significant reduction in nausea and vomiting compared to placebo. Dry mouth was more common in patients receiving scopolamine on days 2 and 3 post-op, and 1 patient reported hallucinations on day 3, thought to be caused by scopolamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8110556']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8110556'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51192791"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, caution is recommended due to increased risks of adverse effects.</p></div>
<div class="block dohp drugH1Div" id="F51192792"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, caution is recommended due to increased risks of adverse effects.</p></div>
<div class="block arsc drugH1Div" id="F56915238"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Anticholinergic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Scopolamine is associated with anticholinergic effects, including <b>xerostomia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6703595','lexi-content-ref-3886352','lexi-content-ref-4950489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6703595','lexi-content-ref-3886352','lexi-content-ref-4950489'])">Ref</a></span>), visual disturbances (eg, <b>blurred vision</b>, <b>mydriasis</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20565460','lexi-content-ref-16719539','lexi-content-ref-4950489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20565460','lexi-content-ref-16719539','lexi-content-ref-4950489'])">Ref</a></span>), and <b>urinary retention</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21118734','lexi-content-ref-20565460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21118734','lexi-content-ref-20565460'])">Ref</a></span>) in adult and pediatric patients. Anticholinergic effects may contribute to nonadherence or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6703595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6703595'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action. Directly related to antagonism of muscarinic receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16719539','lexi-content-ref-16175141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16719539','lexi-content-ref-16175141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; visual disturbances occurred within 1 to 2 days of patch application (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21118734','lexi-content-ref-16175141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21118734','lexi-content-ref-16175141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications that cause anticholinergic adverse reactions (eg, antihistamines, meclizine, tricyclic antidepressants, muscle relaxants)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8545207','lexi-content-ref-24763767','lexi-content-ref-20565460','lexi-content-ref-29192000','lexi-content-ref-31495925','lexi-content-ref-2877187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8545207','lexi-content-ref-24763767','lexi-content-ref-20565460','lexi-content-ref-29192000','lexi-content-ref-31495925','lexi-content-ref-2877187'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">CNS effects such as <b>drowsiness</b> and <b>fatigue</b> may occur with scopolamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3886352','lexi-content-ref-2006245']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3886352','lexi-content-ref-2006245'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Related to the pharmacologic action. Directly related to the antagonism of muscarinic receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Minton.2009','lexi-content-ref-16719539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Minton.2009','lexi-content-ref-16719539'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent alcohol or medications that cause CNS effects (eg, sedatives, hypnotics, opiates, anxiolytics)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30693946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30693946'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8545207','lexi-content-ref-24763767','lexi-content-ref-20565460','lexi-content-ref-29192000','lexi-content-ref-31495925','lexi-content-ref-2877187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8545207','lexi-content-ref-24763767','lexi-content-ref-20565460','lexi-content-ref-29192000','lexi-content-ref-31495925','lexi-content-ref-2877187'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Psychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Scopolamine may cause psychiatric effects, including <b>acute psychosis</b> (ie, <b>delusion,</b>
<b>hallucination</b>), <b>amnesia/memory impairment</b>, <b>agitation</b>, <b>confusion</b>, and <b>speech disturbance</b> in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3886352','lexi-content-ref-24763767','lexi-content-ref-Minton.2009','lexi-content-ref-16719539','lexi-content-ref-16175141','lexi-content-ref-2877187','lexi-content-ref-18834638','lexi-content-ref-3668203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3886352','lexi-content-ref-24763767','lexi-content-ref-Minton.2009','lexi-content-ref-16719539','lexi-content-ref-16175141','lexi-content-ref-2877187','lexi-content-ref-18834638','lexi-content-ref-3668203'])">Ref</a></span>). Psychiatric effects are rare and reversible with discontinuation; may take 1 to 2 days to resolve following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6870212','lexi-content-ref-4027811','lexi-content-ref-18834638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6870212','lexi-content-ref-4027811','lexi-content-ref-18834638'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Directly related to the antagonism of muscarinic receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16719539','lexi-content-ref-3385907']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16719539','lexi-content-ref-3385907'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; abnormal behaviors and psychosis may begin within 1 to 3 days of patch application (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6870212','lexi-content-ref-Minton.2009','lexi-content-ref-18834638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6870212','lexi-content-ref-Minton.2009','lexi-content-ref-18834638'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16719539','lexi-content-ref-3579494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16719539','lexi-content-ref-3579494'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cognitive impairment or dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18834638','lexi-content-ref-3579494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18834638','lexi-content-ref-3579494'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31004425','lexi-content-ref-Minton.2009','lexi-content-ref-16719539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31004425','lexi-content-ref-Minton.2009','lexi-content-ref-16719539'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3668203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3668203'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Withdrawal symptoms following scopolamine discontinuation may include <b>diaphoresis</b>, <b>dizziness</b>, <b>drowsiness</b>, <b>fatigue</b>, <b>headache</b>, <b>hypotension</b>, and <b>nausea</b> in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24715737','lexi-content-ref-26366965','lexi-content-ref-19890085']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24715737','lexi-content-ref-26366965','lexi-content-ref-19890085'])">Ref</a></span>). Resolution of symptoms occurs within several days to weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28081025','lexi-content-ref-24715737','lexi-content-ref-19890085']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28081025','lexi-content-ref-24715737','lexi-content-ref-19890085'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Withdrawal; may be related to muscarinic receptor sensitization, leading to rebound overstimulation of the vestibular nuclei and reticular formation of the vomiting center with discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24715737']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24715737'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; occurs within 18 to 72 hours after removal of the patch (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24715737','lexi-content-ref-19890085']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24715737','lexi-content-ref-19890085'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Prolonged use (≥3 days) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24715737','lexi-content-ref-19890085']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24715737','lexi-content-ref-19890085'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F9522598"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported with transdermal administration. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia (29% to 67%)<span class="lexi-table-link-container"> (<a aria-label="Xerostomia table link" class="lexi-table-link" data-table-id="lexi-content-xerostomia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-xerostomia')">table 1</a>)</span><span class="table-link" style="display:none;">Xerostomia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Xerostomia" frame="border" id="lexi-content-xerostomia" rules="all">
<caption style="text-align:center;">
<b>Scopolamine: Adverse Reaction: Xerostomia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">67%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Nausea and vomiting associated with motion sickness</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">~2/3</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">29%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Post-operative nausea and vomiting</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">461</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">457</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (12%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 2</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (8% to 17%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 3</a>)</span><span class="table-link" style="display:none;">Drowsiness</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Scopolamine: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Post-operative nausea and vomiting</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">461</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">457</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Scopolamine: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">17%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Nausea and vomiting associated with motion sickness</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&lt;1/6</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Post-operative nausea and vomiting</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">461</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">457</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (6%)<span class="lexi-table-link-container"> (<a aria-label="Agitation table link" class="lexi-table-link" data-table-id="lexi-content-agitation" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-agitation')">table 4</a>)</span><span class="table-link" style="display:none;">Agitation</span>, confusion (4%)<span class="lexi-table-link-container"> (<a aria-label="Confusion table link" class="lexi-table-link" data-table-id="lexi-content-confusion" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-confusion')">table 5</a>)</span><span class="table-link" style="display:none;">Confusion</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Agitation" frame="border" id="lexi-content-agitation" rules="all">
<caption style="text-align:center;">
<b>Scopolamine: Adverse Reaction: Agitation</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Post-operative nausea and vomiting</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">461</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">457</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Confusion" frame="border" id="lexi-content-confusion" rules="all">
<caption style="text-align:center;">
<b>Scopolamine: Adverse Reaction: Confusion</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Post-operative nausea and vomiting</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">461</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">457</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Mydriasis (4%)<span class="lexi-table-link-container"> (<a aria-label="Mydriasis table link" class="lexi-table-link" data-table-id="lexi-content-mydriasis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-mydriasis')">table 6</a>)</span><span class="table-link" style="display:none;">Mydriasis</span>, visual impairment (5%)<span class="lexi-table-link-container"> (<a aria-label="Visual Impairment table link" class="lexi-table-link" data-table-id="lexi-content-visual-impairment" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-visual-impairment')">table 7</a>)</span><span class="table-link" style="display:none;">Visual Impairment</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Mydriasis" frame="border" id="lexi-content-mydriasis" rules="all">
<caption style="text-align:center;">
<b>Scopolamine: Adverse Reaction: Mydriasis</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Post-operative nausea and vomiting</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">461</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">457</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Visual Impairment" frame="border" id="lexi-content-visual-impairment" rules="all">
<caption style="text-align:center;">
<b>Scopolamine: Adverse Reaction: Visual Impairment</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Scopolamine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Post-operative nausea and vomiting</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">461</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">457</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (associated with withdrawal) (Manno 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (associated with withdrawal) (Manno 2015), erythema of skin, skin irritation, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (associated with withdrawal) (Manno 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria, urinary retention (Apfel 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application-site burning</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Acute psychosis (Seo 2009), amnesia (Cissold 1985), ataxia (Seo 2009), delirium (Lin 2014, Rozzini 1988), delusion (Seo 2009), disorientation (Seo 2009), disturbance in attention, fatigue (Clissold 1985), hallucination (Seo 2009), headache (Seo 2009), insomnia (Seo 2009), memory impairment (Seo 2009), paranoid ideation, restlessness (Seo 2009), seizure, speech disturbance, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia, angle-closure glaucoma, blurred vision (Nachum 2006), dry eye syndrome, eye pruritus, eyelid pain (irritation), strabismus (Good 1996)</p></div>
<div class="block coi drugH1Div" id="F9522592"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Injection:</p>
<p style="text-indent:-2em;margin-left:4em;">Hyoscine butylbromide [Canadian product]: Hypersensitivity to hyoscine butylbromide, atropinics, or any component of the formulation; untreated narrow-angle glaucoma; megacolon, prostatic hypertrophy with urinary retention; stenotic lesions or mechanical stenosis of the GI tract; myasthenia gravis; tachycardia, angina, heart failure; paralytic or obstructive ileus; IM administration in patients receiving anticoagulant therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">Scopolamine hydrobromide [Canadian product]: Hypersensitivity to scopolamine or any component of the formulation; glaucoma or predisposition to narrow-angle glaucoma; paralytic ileus; prostatic hypertrophy; pyloric obstruction; tachycardia secondary to cardiac insufficiency or thyrotoxicosis.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral [Canadian product]: Hypersensitivity to hyoscine butylbromide, atropinics, or any component of the formulation; glaucoma, megacolon, mechanical stenosis in the GI tract, myasthenia gravis, obstructive prostatic hypertrophy, paralytic or obstructive ileus.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal: Hypersensitivity to scopolamine, other belladonna alkaloids, or any component of the formulation; narrow-angle glaucoma</p></div>
<div class="block war drugH1Div" id="F9522593"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis: Anaphylaxis including episodes of shock has been reported following parenteral administration; observe for signs/symptoms of hypersensitivity following parenteral administration. Patients with a history of allergies or asthma may be at increased risk of hypersensitivity reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bradycardia (paradoxical): Lower doses (0.1mg) may have vagal mimetic effects (eg, increase vagal tone causing paradoxical bradycardia); these effects are likely mediated by blockade of muscarinic receptors at the level of the brain.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with coronary artery disease, tachyarrhythmias, heart failure, or hypertension; evaluate tachycardia prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal (GI) obstruction: Use with caution in patients with GI obstruction; when used for the treatment of smooth muscle spasm of the GI tract avoid continuous (daily) or prolonged use without evaluating source of abdominal pain. Patients should be instructed to report persistent or worsening abdominal pain with or without other symptoms (eg, nausea/vomiting, irregular bowel movements, bloody stool, hypotension).</p>
<p style="text-indent:-2em;margin-left:4em;">• Genitourinary (GU) disease/obstruction: Use with caution in patients with GU obstruction, prostatic hyperplasia, or urinary retention; when used for the treatment of smooth muscle spasm of the GU tract, avoid continuous (daily) or prolonged use without evaluating source of the spasm.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use transdermal product with caution in patients with open-angle glaucoma; may increase intraocular pressure; adjust glaucoma therapy as necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hiatal hernia: Use with caution in patients with hiatal hernia with reflux esophagitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperthyroidism: Use caution in patients with hyperthyroidism; may have increased risk for arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Parkinson disease: Adverse events (including dizziness, headache, nausea, vomiting) may occur following abrupt discontinuation in patients with Parkinson disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychosis: Use with caution in patients with a history of psychosis; may exacerbate condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder; may exacerbate condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ulcerative colitis: Use with caution in patients with ulcerative colitis; may precipitate/aggravate toxic megacolon.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution in pediatric patients since they may be more susceptible to the anticholinergic, neurologic, and psychiatric adverse reactions of scopolamine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fructose: Tablets may contain sucrose; avoid use of tablets in patients who are fructose intolerant.</p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Scopolamine (hyoscine) hydrobromide should not be interchanged with scopolamine butylbromide formulations; dosages are not equivalent.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>
<div class="block foc drugH1Div" id="F9522694"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Patch 72 Hour, Transdermal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Transderm Scop (1.5 MG): 1 MG/3DAYS (4 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Transderm-Scop: 1 MG/3DAYS (1 ea, 10 ea, 24 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 MG/3DAYS (4 ea, 10 ea, 24 ea)</p></div>
<div class="block geq drugH1Div" id="F9522579"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F9522697"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, 72-hour</b> (Scopolamine Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/3days (per each): $22.97 - $24.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Patch, 72-hour</b> (Transderm-Scop Transdermal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/3days (per each): $25.56</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52870235"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as butylbromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Buscopan: 20 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as hydrobromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.4 mg/mL (1 mL); 0.6 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as butylbromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Buscopan: 10 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p></div>
<div class="block adm drugH1Div" id="F9522660"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Butylbromide [Canadian product] or hydrobromide [Canadian product] may be administered by IM, IV, or SubQ injection.</p>
<p style="text-indent:-2em;margin-left:2em;">IM: <b>Butylbromide:</b> Intramuscular injections should be administered 10 to 15 minutes prior to radiological/diagnostic procedures.</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Butylbromide:</b> No dilution is necessary prior to injection; inject at a rate of 1 mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hydrobromide:</b> No dilution is necessary prior to injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral [Canadian product]: Tablet should be swallowed whole and taken with a full glass of water.</p>
<p style="text-indent:-2em;margin-left:2em;">Transdermal: Apply to hairless area of skin behind the ear. Wear only one patch at a time; remove first patch and apply new patch behind the other ear. Wash hands before and after applying the patch to avoid drug contact with eyes. Do not cut the patch. Once patch has been affixed behind the ear, do not touch while being worn since pressure may cause scopolamine to release at the edge. Topical patch is programmed to deliver 1 mg over 3 days. Once applied, do not remove the patch for 3 full days (motion sickness). When used postoperatively for nausea/vomiting, the patch should be removed 24 hours after surgery. If patch becomes displaced, discard and apply a new patch. Once removed, fold the used patch in half with the sticky side together; dispose of used patches in the trash out of reach from children and pets.</p></div>
<div class="block admp drugH1Div" id="F52614406"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Transdermal: Apply patch to hairless area behind 1 ear. Do not wear more than 1 patch at a time. Wash hands before and after application of disc to avoid drug contact with eyes. Transdermal patch is designed to deliver 1 mg over 3 days. Do not use any patch that has been damaged, cut, or manipulated in any way. If necessary to use smaller patch increments, do not cut patch; remove only portions of the backing required for the dose (eg, if <sup>1</sup>/<sub>2</sub> patch is needed, remove only <sup>1</sup>/<sub>2</sub> of the backing prior to application), cover with occlusive dressing to keep in place (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32943036','lexi-content-ref-29192000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32943036','lexi-content-ref-29192000'])">Ref</a></span>). If patch becomes displaced, discard and apply a new patch behind the other ear. Once removed, fold the used patch in half with the sticky side together; dispose of used patches in the trash out of reach from children and pets.</p></div>
<div class="block use drugH1Div" id="F9522580"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastrointestinal/genitourinary spasm (scopolamine butylbromide [Canadian product]):</b> Treatment of abdominal spasms and pain and discomfort in the stomach, bowels, and biliary tract; prevention of spasm prior to radiological or diagnostic procedures. May also be used off label for management of pain associated with smooth muscle spasms in the urinary tract (Tytgat 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Motion sickness, prevention (scopolamine base):</b> Prevention of nausea and vomiting associated with motion sickness.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Postoperative nausea and/or vomiting, prevention (scopolamine base):</b> Prevention of postoperative nausea and vomiting associated with recovery from anesthesia or opioid analgesia and surgery.</p></div>
<div class="block off-label drugH1Div" id="F56053514"><span class="drugH1">Use: Off-Label: Adult</span><p>Malignant bowel obstruction, inoperable; Sialorrhea; Terminal airway secretions (death rattle)</p></div>
<div class="block mst drugH1Div" id="F9522566"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Scopolamine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its highly anticholinergic properties and uncertain effectiveness as an antispasmodic (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300031"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9522602"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Anticholinergic Agents may enhance the anticholinergic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F9522582"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Scopolamine crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">When the transdermal patch is used to prevent nausea and vomiting associated with surgery, dose adjustments are required prior to cesarean delivery. Avoid use of transdermal patches in pregnant patients with severe preeclampsia; eclamptic seizures have been reported after IV and IM use.</p></div>
<div class="block brc drugH1Div" id="F20688484"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Scopolamine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. The Academy of Breastfeeding Medicine (ABM) states that scopolamine used as an antiemetic in the perioperative period is likely safe; however, because scopolamine may cause maternal sedation and adversely affect milk supply with repeated doses, other agents may be preferred (ABM [Reece-Stremtan 2017]).</p></div>
<div class="block mop drugH1Div" id="F9522664"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Body temperature, heart rate, urinary output, intraocular pressure, mental alertness.</p></div>
<div class="block pha drugH1Div" id="F9522628"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands and the CNS; increases cardiac output, dries secretions, antagonizes histamine and serotonin; at usual recommended doses, causes blockade of muscarinic receptors at the cardiac SA-node and is parasympatholytic (ie, blocks vagal activity increasing heart rate)</p></div>
<div class="block phk drugH1Div" id="F9522630"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Butylbromide: Injection: ≤15 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Hydrobromide: Injection: ~15 minutes (Renner 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">Scopolamine base: Transdermal: 6 to 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Hydrobromide: Injection: ~4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Scopolamine base: Transdermal: 72 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Butylbromide: Oral: Quaternary salts are poorly absorbed (local concentrations in the GI tract following oral dosing may be high).</p>
<p style="text-indent:-2em;margin-left:4em;">Hydrobromide: IM, SubQ: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Butylbromide: 128 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Butylbromide: ~4% (albumin).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Butylbromide: Oral: 8%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Butylbromide: Terminal: IV: ~5 hours; Oral: ~6 to 11 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Hydrobromide: Injection: ~1 to 3.5 hours (Renner 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">Scopolamine base: Transdermal: 9.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Butylbromide: Oral: ~2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Hydrobromide: IM: ~20 minutes; IV: ~5 minutes; SubQ: ~15 minutes (Renner 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">Scopolamine base: Transdermal: 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;">Butylbromide: IV: Urine (42% to 61% [half as parent drug]), feces (28% to 37%).</p>
<p style="text-indent:-2em;margin-left:4em;">Hydrobromide: Injection: Urine (variable; as parent drug and metabolites) (Renner 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">Scopolamine base: Transdermal: Urine (&lt;10%, as parent drug and metabolites).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10962006"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Hycom | Riaspasm | Scopinal | Spasmonore | Spasmopan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Buscapina | Cifespasmo | Colobolina | Excelentia antiespasmodico | Hioscina vannier | Luar g</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Buscopan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amcal Stomach Ache &amp; Pain Relief | Apohealth stomach ease forte | Buscopan | Buscopan Forte | Chemists Own Stomach Ache &amp; Pain Relief | Chemists' own stomach ache &amp; pain relief double strength | Gastro soothe | Guardian Stomach Ache &amp; Pain Relief | Pharmacor Stomach Ease | Pharmacy care stomach ache &amp; pain relief double strength | Setacol | Stomach ache &amp; pain relief | Stomach ease | Stomex | Terry white chemists stomach ease | Terrywhite chemmart stomach relief forte | Trust stomach ease</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Anticol | Asipan | Belcopan | Bromid | Brospan | Buscocin | Buscon | Buskogen | Butacin | Butalpen | Butapan | Butason | Butastat | Butyl K | Colik | Hylac | Hyo | Hyosin | Hysin | Hyso | Hysocin | Hysoma | Hysomide | Hysopain | Hysopan | Relapan | Resopan | Sinumid | Spa | Spanil | Spasmonil | Spasmoson | Typan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Buscopan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Buscolysin | Buscomed | Buscopan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Algexin | Belscopan | Buscopan | Butilbrometo de escopolamina | Colipan | Furp hioscina | Hioscina | Uni hioscin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Buscopan</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Buscapina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Scopolamine butylbromide</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Buscapina | Butilbromuro de hioscina | Colespas | Diuxoton | Espasmobil S | Fin espam | Hioscina butil bromuro | Hioscina butilbromuro | Hioscina n butil bromuro | Hioscina n butilbromuro | Labinpina | N butil bromuro de hioscina | N-butil bromuro de hioscina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Scobutil</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bs | Buscopan | Espa butyl | Hyoscin n butylbr.</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Brolamina | Buscapina | Cryopina | Estalan | Tirel</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Buscapina | Espasmotab</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Buscopan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Butacid | Nu spasm | Spasmocin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Buscapina | Butilescopolamina aurovitas</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Ascopan | Dividol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Buscopan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Buscopan cramps | Buscopan ibs relief</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Buscopan relief | Minispasm</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Buscon | Buscopalamin | Buscopan | Busmin | Busopin | Buspan | Cencopan S | Colospan | Dhacopan | Dividol | Europon | Hyomide | Hyoscine | Hyospan | Hyospasmol | Hyscopan | Neo busco | Scolopon | Scopalamin | Scopol | Scopomin | Spascopan | Spasmoliv | U busco | Vesuton | Vidaspan</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Buscol | Buscopan</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Buscopan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Buscotica | Dormi | Hyoscine-N-Butyl Bromide Ogb | Hyosincap | Hyscopan | Scopamin | Scopma | Spasmeco | Spasmolit | Stomica</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Buscopan ibs relief</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Belloid | Buscogast | Buscomol | Buscopan | Gastreco | Hyocimax | Hyocimax forte | Hyospan | Hyoswift | Spaslin-h</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">As spasmo | Piocine | Spasmoban dij | Spasmodain | Spasmosam | Spasmostop | Spasmotab</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Addofix | Buscopan | Erion</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Scopinal | Spasmonor | Spasmopan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alcopin m | Amisepan | Bubusco s | Bulospan | Buscolamin | Buscom | Buscopan | Buscopan a | Buscopan a boehringer | Buscopan a tanabe | Buscote | Busfoliron | Busfoliron tsuruhara | Buspon | Butibol | Butiburon | Butiscomin | Butylmido | Butylmin | Butylpan | Butylscopol.bro.am | Butylscopol.hexal | Butysco | C b scopola nichiiko | C b scopola yoshindo | C.b.scopola | Diaste m | Fujisco a | Fujisco v | Gosper f | Hiyosin | Hyospan | Inosco | Monospan | Reladan | Scobron | Scobutylamin | Scordin b hachi | Sparicon | Spasmopan | Stoma off | Tyaspan | Viviv</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Ascopan | Bispanol | Bukol | Buscopan | Duxcospan | Hycin | Hycom | Hyodol | Hyomide | Hyospan | Nospasum | Oraspas | Scospan | Spanil | Spaslin-h | Spasmed | Spasmin | Spasmintas | Spaszed | Unicine</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bispan | Bromcopang | Brospan | Bucomin | Bupain | Buscopan | Buscopan sct | Buspin | Hybropan | Hyspan | Scolmin | Sparicon | Spolamine | Unispan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Butacid | Scopinal | Spasmocin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Scopinal</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Buscolysin | Buscopan | Scobutil | Scopolan</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Buscopan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bs Carino | Buscolysin | Buscopan | Scobutil</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Spasmopan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Anprevad | Biomesina | Brolamina | Brupacil | Buscapina | Butilhioscina | Butilhioscina Bruluart | Butilhioscina gi s | Butilhioscina keye | Butiral | Capin bh | Cryopina | Desdanil | Diasil | Espacil | Espadiva teens | Grafin | Hiosultrina | Lemophar | Liliam | Pasmodil pfc | Serralpina | Tilosin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Buspan | Butyscol | Colospan | Copan | Dhacopan | Fucon | Hyomide | Hyoscine | Hyoscine Butylbromine | Hyoscine Pharmaniaga | Scopan | Spasmoliv | Vascopan</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Balsoban | Buscopan | Celoscopan | Cinex | Darvinks hyoscine | Derm hyoscine | Eminent hyoscine butylbromide | Feccox hyoscine butylbromide | Geneith | Hyoscine | Nci hyoscine | Noyosyne | Rico hyoscine butylbromide | Ultpan | Zuna hyo</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Buscopan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Buscopan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Buscopan Forte | Gastro soothe</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Buscamol | Buscapina | Escapin | Espasmex | Hioscina butil bromuro | Hiosdol | Hiosimol | Modul</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ascopen | Belloid | Buscomed | Buscopan | Busopin | Cospan | Fucon | Hayospan | Hiospan | Hizon hyoscine hydrobromide | Hyomide | Hyos | Hyosaph | Hyoscine | Hyospan | Oraspas | Scolmin | Spasmolysin | Spasrelief</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Hycin | Hyoscine | Hysopan | Maqcine</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Scobutil | Scopolan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Butilescopolamina conforpam</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Buscapina</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Antipan | Buscopan | Hycom | Hyopan | Nospasm | Riaspasm | Scopinal | Spasmopan</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Buscorem | Buscotil | Uscosin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Buscopan</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Hyoban | Nospasm | Riaspasm | Scopinal | Spasmonore | Spasmopan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Colospan | Dhacopan | Hyomide | SP-Anspaz | Spasmoliv</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Buscol | Buscopan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Buscopan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Amcopan | Antispa | Bacotan | Bascan | Batocine | Buscol | Buscono | Buscopan | Busopac | Buspan | Butyl | Cencopan | Eralga | Higan | Hiogan | Hy-spa | Hyoscine b m | Hyoscine Star | Hyosman | Hyosmed | Hyospan | Hyostan | Hyozin | Hytic | Mucopan | Muskopan | Myspa | Oscin | Paroscin | Pincine | Scopas | Spas-x | Spascopan | Spasgone-h | Spasmo | Spatab | Spatyl | Sunagan | Terca | Unspasic | Uospan | Vacopan</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Spasmopan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Butopan | Skopan | Spazmotek</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ariel | Bispan | Boscon | Brosco | Buscin | Buscopan | Buscoton | Busfoliron | Buskobun | Buspan | Buston | Butopan | Butosan | Butylpan | Butypon | Butysco | Butyscol | Che su | Despas | Dettacks | Dividol | Fucon | Gastropan | Hyopan | Kapin | Kascopan | Koscopan | Lihosin | Linton | Pusko | Regicopan S | Scomine | Sconin | Scopam | Scopolamine | Secopon | Spoline | Suspan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Spasmobru</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Ascopan sc | Bispanol | Bukol | Hbb | Hyospan</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bupasmol | Buscapina</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Atroveran | Buscapina | Butilbromuro de hioscina | Butilbromuro hioscina | Hioscina | Hioscina n butilbromuro</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Busmocalm</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Buscopan | Hyospasmol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ascopan | Bukol | Colospan | Hyomide | Hyscin | Pharma q hyoscine butylbromide | Spasminal | Spasmintas | Spasmorid</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Hyospasmol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30693946">
<a name="30693946"></a>2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2019;67(4):674-694. doi:10.1111/jgs.15767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/30693946/pubmed" id="30693946" target="_blank">30693946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32943036">
<a name="32943036"></a>Al Jeraisy M, AlFuraih M, AlSaif R, AlKhalifah B, AlOtaibi H, Abolfotouh MA. Efficacy of scopolamine transdermal patch in children with sialorrhea in a pediatric tertiary care hospital. <i>BMC Pediatr</i>. 2020;20(1):437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/32943036/pubmed" id="32943036" target="_blank">32943036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21118734">
<a name="21118734"></a>Apfel CC, Zhang K, George E, et al. Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis. <i>Clin Ther</i>. 2010;32(12):1987-2002. doi:10.1016/j.clinthera.2010.11.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/21118734/pubmed" id="21118734" target="_blank">21118734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6703595">
<a name="6703595"></a>Babin RW, Balkany TJ, Fee WE. Transdermal scopolamine in the treatment of acute vertigo. <i>Ann Otol Rhinol Laryngol</i>. 1984;93(1 Pt 1):25-7. doi:10.1177/000348948409300106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/6703595/pubmed" id="6703595" target="_blank">6703595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19698013">
<a name="19698013"></a>Bar R, Gil A, Tal D. Safety of double-dose transdermal scopolamine. <i>Pharmacotherapy</i>. 2009;29(9):1082-1088. doi:10.1592/phco.29.9.1082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/19698013/pubmed" id="19698013" target="_blank">19698013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12380654">
<a name="12380654"></a>Bennett M, Lucas V, Brennan M, Hughes A, O'Donnell V, Wee B; Association for Palliative Medicine's Science Committee. Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care. <i>Palliat Med</i>. 2002;16(5):369-374. doi:10.1191/0269216302pm584oa<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/12380654/pubmed" id="12380654" target="_blank">12380654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25882751">
<a name="25882751"></a>Brandt JC, Harman E, Winchester D. An unusual case of nonsustained ventricular tachycardia. <i>Ther Adv Cardiovasc Dis</i>. 2015;9(3):103-106. doi:10.1177/1753944715581137<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/25882751/pubmed" id="25882751" target="_blank">25882751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3047394">
<a name="3047394"></a>Brodtkorb E, Wyzocka-Bakowska MM, Lillevold PE, Sandvik L, Saunte C, Hestnes A. Transdermal scopolamine in drooling. <i>J Ment Defic Res</i>. 1988;32(pt 3):233-237. doi:10.1111/j.1365-2788.1988.tb01409.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/3047394/pubmed" id="3047394" target="_blank">3047394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Buscopan.1">
<a name="Buscopan.1"></a>Buscopan (scopolamine) tablets and injection, solution [product monograph]. Laval, Quebec, Canada: Sanofi Consumer Health Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6870212">
<a name="6870212"></a>Cairncross JG. Scopolamine psychosis revisited. <i>Ann Neurol</i>. 1983;13(5):582. doi:10.1002/ana.410130524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/6870212/pubmed" id="6870212" target="_blank">6870212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28081025">
<a name="28081025"></a>Chowdhury NA, Sewatsky ML, Kim H. Transdermal scopolamine withdrawal syndrome case report in the pediatric cerebral palsy population. <i>Am J Phys Med Rehabil</i>. 2017;96(8):e151-e154. doi:10.1097/PHM.0000000000000665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/28081025/pubmed" id="28081025" target="_blank">28081025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3886352">
<a name="3886352"></a>Clissold SP, Heel RC. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy. <i>Drugs</i>. 1985;29(3):189-207. doi:10.2165/00003495-198529030-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/3886352/pubmed" id="3886352" target="_blank">3886352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2006245">
<a name="2006245"></a>Curran HV, Schifano F, Lader M. Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood. <i>Psychopharmacology (Berl)</i>. 1991;103(1):83-90. doi:10.1007/BF02244079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/2006245/pubmed" id="2006245" target="_blank">2006245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8110556">
<a name="8110556"></a>Doyle E, Byers G, McNicol LR, Morton NS. Prevention of postoperative nausea and vomiting with transdermal hyoscine in children using patient-controlled analgesia. <i>Br J Anaesth</i>. 1994;72(1):72-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/8110556/pubmed" id="8110556" target="_blank">8110556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Galvagno.1">
<a name="Galvagno.1"></a>Galvagno S, Sappenfield J. Anesthesia for adult trauma patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32467512">
<a name="32467512"></a>Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2020;131(2):411-448. doi:10.1213/ANE.0000000000004833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/32467512/pubmed" id="32467512" target="_blank">32467512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8545207">
<a name="8545207"></a>Good WV, Crain LS. Esotropia in a child treated with a scopolamine patch for drooling. <i>Pediatrics</i>. 1996;97(1):126-127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/8545207/pubmed" id="8545207" target="_blank">8545207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Grant.1">
<a name="Grant.1"></a>Grant GJ. Pharmacologic management of pain during labor and delivery. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Harman.1">
<a name="Harman.1"></a>Harman S, Walling AM. Palliative care: the last hours and days of life. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2065410">
<a name="2065410"></a>Horimoto Y, Tomie H, Hanzawa K, Nishida Y. Scopolamine patch reduces postoperative emesis in paediatric patients following strabismus surgery. <i>Can J Anaesth</i>. 1991;38(4, pt 1):441-444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/2065410/pubmed" id="2065410" target="_blank">2065410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10858832">
<a name="10858832"></a>Hughes A, Wilcock A, Corcoran R, Lucas V, King A. Audit of three antimuscarinic drugs for managing retained secretions. <i>Palliat Med</i>. 2000;14(3):221-222. doi:10.1191/026921600670188257<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/10858832/pubmed" id="10858832" target="_blank">10858832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ICSI.1">
<a name="ICSI.1"></a>Institute for Clinical Systems Improvement (ICSI). Health Care Guideline: Perioperative. 6th ed. https://www.icsi.org/wp-content/uploads/2020/01/Periop_6th-Ed_2020_v2.pdf. Published January 2020. Accessed August 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IAHPC.1">
<a name="IAHPC.1"></a>International Association for Hospice and Palliative Care (IAHPC). <i>The IAHPC Manual of Palliative Care</i>. 3rd ed. International Association for Hospice and Palliative Care; 2013. https://hospicecare.com/what-we-do/publications/manual-of-palliative-care/. Accessed August 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19337628">
<a name="19337628"></a>Khalif IL, Quigley EM, Makarchuk PA, Golovenko OV, Podmarenkova LF, Dzhanayev YA. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics). <i>J Gastrointestin Liver Dis</i>. 2009;18(1):17-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/19337628/pubmed" id="19337628" target="_blank">19337628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31004425">
<a name="31004425"></a>Knuf KM, Spaulding FM, Stevens GJ. Scopolamine toxicity in an elderly patient. <i>Mil Med</i>. 2019;184(11-12):937-938. doi:10.1093/milmed/usz086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/31004425/pubmed" id="31004425" target="_blank">31004425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33315591">
<a name="33315591"></a>Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. <i>Am J Gastroenterol</i>. 2021;116(1):17-44. doi:10.14309/ajg.0000000000001036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/33315591/pubmed" id="33315591" target="_blank">33315591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23865591">
<a name="23865591"></a>Lacy BE, Wang F, Bhowal S, Schaefer E; study group. On-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain. <i>Scand J Gastroenterol</i>. 2013;48(8):926-935. doi:10.3109/00365521.2013.804117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/23865591/pubmed" id="23865591" target="_blank">23865591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24715737">
<a name="24715737"></a>Lau SH, Vaneaton C. Scopolamine patch withdrawal syndrome. <i>Hosp Pharm</i>. 2014;49(3):218-220. doi:10.1310/hpj4903-218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/24715737/pubmed" id="24715737" target="_blank">24715737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7516297">
<a name="7516297"></a>Lewis DW, Fontana C, Mehallick LK, Everett Y. Transdermal scopolamine for reduction of drooling in developmentally delayed children. <i>Dev Med Child Neurol</i>. 1994;36(6):484-486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/7516297/pubmed" id="7516297" target="_blank">7516297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24763767">
<a name="24763767"></a>Lin CH, Lung HL, Li ST, Lin CY. Delirium after transdermal scopolamine patch in two children. <i>J Neuropsychiatry Clin Neurosci</i>. 2014;26(2):E01-E2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/24763767/pubmed" id="24763767" target="_blank">24763767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4027811">
<a name="4027811"></a>MacEwan GW, Remick RA, Noone JA. Psychosis due to transdermally administered scopolamine. <i>CMAJ</i>. 1985;133(5):431-432.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/4027811/pubmed" id="4027811" target="_blank">4027811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35274188">
<a name="35274188"></a>Madariaga A, Lau J, Ghoshal A, et al. MASCC multidisciplinary evidence-based recommendations for the management of malignant bowel obstruction in advanced cancer. <i>Support Care Cancer</i>. 2022;30(6):4711-4728. doi:10.1007/s00520-022-06889-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/35274188/pubmed" id="35274188" target="_blank">35274188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26366965">
<a name="26366965"></a>Manno M, Di Renzo G, Bianco P, Sbordone C, De Matteis F. Unique scopolamine withdrawal syndrome after standard transdermal use. <i>Clin Neuropharmacol</i>. 2015;38(5):204-205. doi:10.1097/WNF.0000000000000099<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/26366965/pubmed" id="26366965" target="_blank">26366965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20565460">
<a name="20565460"></a>Mato A, Limeres J, Tomás I, et al. Management of drooling in disabled patients with scopolamine patches. <i>Br J Clin Pharmacol</i>. 2010;69(6):684-688. doi:10.1111/j.1365-2125.2010.03659.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/20565460/pubmed" id="20565460" target="_blank">20565460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17280927">
<a name="17280927"></a>Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. <i>J Pain Symptom Manage</i>. 2007;33(2):217-223. doi:10.1016/j.jpainsymman.2006.06.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/17280927/pubmed" id="17280927" target="_blank">17280927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10789958">
<a name="10789958"></a>Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. <i>Support Care Cancer</i>. 2000;8(3):188-191. doi:10.1007/s005200050283<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/10789958/pubmed" id="10789958" target="_blank">10789958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Minton.2009">
<a name="Minton.2009"></a>Minton JA, Tofade TS, Shah SA. Psychosis from anticholinergic medications administered at a smoking cessation clinic. <i>Journal of Pharmacy Practice</i>. 2009;22(5):489-493.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16817918">
<a name="16817918"></a>Mueller-Lissner S, Tytgat GN, Paulo LG, et al. Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. <i>Aliment Pharmacol Ther</i>. 2006;23(12):1741-1748. doi:10.1111/j.1365-2036.2006.02818.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/16817918/pubmed" id="16817918" target="_blank">16817918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16719539">
<a name="16719539"></a>Nachum Z, Shupak A, Gordon CR. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. <i>Clin Pharmacokinet</i>. 2006;45(6):543-66. doi:10.2165/00003088-200645060-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/16719539/pubmed" id="16719539" target="_blank">16719539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29192000">
<a name="29192000"></a>Parr JR, Todhunter E, Pennington L, et al. Drooling reduction intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability. <i>Arch Dis Child</i>. 2018;103(4):371-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/29192000/pubmed" id="29192000" target="_blank">29192000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19890085">
<a name="19890085"></a>Patel PN, Ezzo DC. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine. <i>Am J Health Syst Pharm</i>. 2009;66(22):2024-2026. doi:10.2146/ajhp080569<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/19890085/pubmed" id="19890085" target="_blank">19890085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25889313">
<a name="25889313"></a>Peng X, Wang P, Li S, Zhang G, Hu S. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. <i>World J Surg Oncol</i>. 2015;13:50. doi:10.1186/s12957-015-0455-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/25889313/pubmed" id="25889313" target="_blank">25889313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21773046">
<a name="21773046"></a>Pergolizzi JV, Raffa R, Taylor R. Prophylaxis of postoperative nausea and vomiting in adolescent patients: a review with emphasis on combination of fixed-dose ondansetron and transdermal scopolamine. <i>J Drug Deliv</i>. 2011;2011:426813.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/21773046/pubmed" id="21773046" target="_blank">21773046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Reece-Stremtan.1">
<a name="Reece-Stremtan.1"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine (ABM). ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31495925">
<a name="31495925"></a>Reid SM, Westbury C, Guzys AT, Reddihough DS. Anticholinergic medications for reducing drooling in children with developmental disability. <i>Dev Med Child Neurol</i>. 2020;62(3):346-353.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/31495925/pubmed" id="31495925" target="_blank">31495925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7639364">
<a name="7639364"></a>Reinhart DJ, Klein KW, Schroff E. Transdermal scopolamine for the reduction of postoperative nausea in outpatient ear surgery: a double-blind, randomized study. <i>Anesth Analg</i>. 1994;79(2):281-284. doi:10.1213/00000539-199408000-00013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/7639364/pubmed" id="7639364" target="_blank">7639364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16175141">
<a name="16175141"></a>Renner UD, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. <i>Ther Drug Monit</i>. 2005;27(5):655-665. doi:10.1097/01.ftd.0000168293.48226.57<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/16175141/pubmed" id="16175141" target="_blank">16175141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3385907">
<a name="3385907"></a>Rozzini R, Inzoli M, Trabucchï M. Delirium from transdermal scopolamine in an elderly woman. <i>JAMA</i>. 1988;260(4):478.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/3385907/pubmed" id="3385907" target="_blank">3385907</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4950489">
<a name="4950489"></a>Safer DJ, Allen RP. The central effects of scopolamine in man. <i>Biol Psychiatry</i>. 1971;3(4):347-355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/4950489/pubmed" id="4950489" target="_blank">4950489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Omega.1">
<a name="Omega.1"></a>Scopolamine hydrobromide injection [product monograph]. Montreal, Canada: Omega; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2877187">
<a name="2877187"></a>Sennhauser FH, Schwarz HP. Toxic psychosis from transdermal scopolamine in a child. <i>Lancet</i>. 1986;2(8514):1033.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/2877187/pubmed" id="2877187" target="_blank">2877187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18834638">
<a name="18834638"></a>Seo SW, Suh MK, Chin J, Na DL. Mental confusion associated with scopolamine patch in elderly with mild cognitive impairment (MCI). <i>Arch Gerontol Geriatr</i>. 2009;49(2):204-207. doi:10.1016/j.archger.2008.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/18834638/pubmed" id="18834638" target="_blank">18834638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3579494">
<a name="3579494"></a>Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA 3rd, Murphy DL. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study. <i>Arch Gen Psychiatry</i>. 1987;44(5):418-426. doi:10.1001/archpsyc.1987.01800170032006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/3579494/pubmed" id="3579494" target="_blank">3579494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxter.1">
<a name="Baxter.1"></a>Transderm Scop (scopolamine) [prescribing information]. Deerfield, IL: Baxter Healthcare; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17547475">
<a name="17547475"></a>Tytgat GN. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. <i>Drugs</i>. 2007;67(9):1343-1357. doi:10.2165/00003495-200767090-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/17547475/pubmed" id="17547475" target="_blank">17547475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34609452">
<a name="34609452"></a>van Esch HJ, van Zuylen L, Geijteman ECT, et al. Effect of prophylactic subcutaneous scopolamine butylbromide on death rattle in patients at the end of life: The SILENCE randomized clinical trial. <i>JAMA</i>. 2021;326(13):1268-1276. doi:10.1001/jama.2021.14785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/34609452/pubmed" id="34609452" target="_blank">34609452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilcock.1">
<a name="Wilcock.1"></a>Wilcock A, Howard P, Charlesworth S, eds. <i>Palliative Care Formulary</i>. 7th ed. Pharmaceutical Press; 2020. https://www.pharmpress.com/product/9780857113689/pcf. Accessed August 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19361952">
<a name="19361952"></a>Wildiers H, Dhaenekint C, Demeulenaere P, et al; Flemish Federation of Palliative Care. Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. <i>J Pain Symptom Manage</i>. 2009;38(1):124-133. doi:10.1016/j.jpainsymman.2008.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/19361952/pubmed" id="19361952" target="_blank">19361952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3668203">
<a name="3668203"></a>Wilkinson JA. Side effects of transdermal scopolamine. <i>J Emerg Med</i>. 1987;5(5):389-392. doi:10.1016/0736-4679(87)90144-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/scopolamine-hyoscine-drug-information/abstract-text/3668203/pubmed" id="3668203" target="_blank">3668203</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9915 Version 385.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
